Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on ...
FARMINGTON HILLS, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, …